CSD/BSE&NSE/PR/2026-2027
Date: November 16, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Revised - News Release

With reference to above subject, please find enclosed Revised - News Release of our company titled **Suven Life Sciences to present "*Masupirdine Phase-3 Baseline Demographic & Clinical Characteristics*" and "*Tenaclidine Phase-1 First-In-Human Safety, Tolerability, Pharmacokinetics*" at the 19th Clinical Trials on Alzheimer's Disease (CTAD-2026) Conference at Boston, USA.**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**
Kandari Sangeetha Laxmi
Digitally signed by Kandari Sangeetha Laxmi
Date: 2026.11.16 12:14:38 +05'30'
K. Sangeetha Laxmi
Company Secretary

Encl.: as above

News Release

Suven Life Sciences to present "*Masupirdine Phase-3 Baseline Demographic & Clinical Characteristics*" and "*Tenaclidine Phase-1 First-In-Human Safety, Tolerability, Pharmacokinetics*" at the 19th Clinical Trials on Alzheimer's Disease (CTAD-2026) Conference at Boston, USA.

Hyderabad, India, 16-Nov-2026: Suven Life Sciences, a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, announced that it will present two scientific presentations highlighting the clinical progress of its investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place during 16-19, November, 2026, at Boston, USA.

CTAD is a global forum dedicated exclusively to Alzheimer's disease clinical research, bringing together investigators, clinicians, industry scientists, and regulatory experts committed to advancing the field. CTAD fosters a collective scientific experience, encourages in-depth dialogue, and creates meaningful interactions across disciplines and offers an opportunity to engage with key opinion leaders, clinical trial specialists, regulatory representatives, and multidisciplinary research teams, while gaining insight into the latest advances shaping prevention and treatment strategies.

Suven presentations at CTAD:

P033: ***Masupirdine (SUVN-502), A Pure 5-HT$_6$ Receptor Antagonist: Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type*** **-** Baseline demographic and clinical characteristics of patients enrolled in the global Phase-3 study of Masupirdine will be presented.

P066: ***Tenaclidine (SUVN-I6107), A Pure M1 Positive Allosteric Modulator First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects*** **-** Outcome from the Phase-1 single ascending dose (SAD) and multiple ascending dose (MAD) studies of Tenaclidine (SUVN-I6107) in healthy subjects, including safety, tolerability and pharmacokinetics, as well as the effects of food, age and gender on its pharmacokinetic profile will be presented.

*"Completion of enrolment in the global Phase-3 Masupirdine AAD study marks an important milestone in the clinical development. Very glad to report the b*aseline *characteristics are consistent with the published studies, representative of quality AD population with Agitation and no major safety concerns have been identified to date. We look forward to the topline results as scheduled in Q2-2027. We are very encouraged by the clinical findings for Tenaclidine, to move forward to the patient studies. The progress reflects our continued efforts to advance innovative therapeutic approaches addressing significant unmet needs in CNS disorders"* said Mr. Venkat Jasti, Chairman and Managing Director, Suven Life Sciences.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing, enrollment completed); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; pivotal Phase-3 AWAKE study for EDS is initiated and Phase-2 study for Cataplexy is in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study completed and Phase-3 study is in planning); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), Tenaclidine (SUVN-I6107) for cognitive disorders (Phase-1 study is completed; Long term general toxicity and developmental toxicity studies in nonclinical models are in progress). In addition to these clinical assets, seven projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major world markets.

For more information, please visit our website http://www.suven.com.

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*